Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era

Kelly, Michael E.; Murphy, Edward; Keyes, Alan; Khan, Mohammad Faraz; Bolger, Jarlath; Grundy, Josh; Conneely, John; MacHale, John; McCaffrey, John; Ra, Chisei; Moran, Brendan; Shields, Conor; Mulsow, Jürgen

doi:10.1007/s11845-021-02506-5

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[61][62][63] In countries with government-funded health care, centralization of CRS has been required to provide cost-effective care with acceptable perioperative morbidity and mortality. [64][65][66] However, it is important to acknowledge that these specialized centers in LMIC will Most registries focused on collecting data on patients undergoing CRS and HIPEC, while two registries included all patients with peritoneal carcinomatosis. The primary use of registries was to track outcomes and complications.…”

Section: Strategies For Improving the Adoption Of Crsmentioning

confidence: 99%

“…Several studies from the Netherlands, where surgery for peritoneal surface malignancies is performed in specialized centers, have reported improved patient selection, treatment determination, and overall outcomes 61–63 . In countries with government‐funded health care, centralization of CRS has been required to provide cost‐effective care with acceptable perioperative morbidity and mortality 64–66 . However, it is important to acknowledge that these specialized centers in LMIC will often be located in urban areas leading to access challenges for patients from rural regions with inadequate resources.…”

Section: Global Trends In the Adoption Of Crsmentioning

confidence: 99%

See 1 more Smart Citation

Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends

Sedighim,

Khan,

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) has now been accepted as an integral component in the management of gastrointestinal and gynecological cancers with peritoneal metastases. Since the adoption of CRS is influenced by access to advanced medical facilities, trained multidisciplinary teams, and funding, there is wide variability in incorporation of CRS into routine clinical practice between high‐ versus low‐ and middle‐income countries. This review highlights the global trends in the adoption of CRS for peritoneal malignancies with a specific focus on the establishment of CRS programs and barriers to incorporate CRS into routine clinical care in low‐ and middle‐income countries.

show abstract

Section: Strategies For Improving the Adoption Of Crsmentioning

confidence: 99%

Section: Global Trends In the Adoption Of Crsmentioning

confidence: 99%

Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends

Sedighim,

Khan,

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer

Dagenborg,

Brudvik,

Lund-Andersen

et al. 2024

Annals of Surgery

View full text Add to dashboard Cite

Background: Colorectal cancer frequently metastasize to the liver and peritoneum, and is associated with a poor prognosis. In selected patients, a benefit in overall survival (OS) was shown for both peritoneal metastases (PM-CRC) offered cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), and colorectal liver metastases (CLM) treated with surgical resection. However, the presence of CLM was considered a relative contraindication to CRS-HIPEC, causing a paucity in outcome data in this patient group. Study design: Patient with PM-CRC having CRS-HIPEC at a single national center between 2007 and 2023, with additional intervention for CLM, were included (previous curative treatment for extra-peritoneal and extra-hepatic metastases was allowed). Three groups were defined: CLM before CRS-HIPEC (preCRS-HIPEC); CLM resected simultaneously with CRS-HIPEC (simCRS-HIPEC); CLM after CRS-HIPEC (postCRS-HIPEC), aiming to retrospectively analyze outcomes. Results: Fifty-seven patients were included and classified as: preCRS-HIPEC (n=11), simCRS-HIPEC (n=29), and postCRS-HIPEC (n=17). Median peritoneal cancer index (PCI) was 8, 13 patients had severe complications (Clavien-Dindo ≥3), and no 90-day mortality. Median OS was 48 months after CRS-HIPEC. PCI was a predictor of OS (HR 1.11, P<0.001). We observed no difference in short or long-term outcomes between intervention groups. Discussion: This study demonstrate that patients with CLM having CRS-HIPEC had comparable OS to reports on CRS-HIPEC only, likely explained by a low PCI. Simultaneous CLM resection did not increase the risk of severe complications. Conclusion: In this national cohort, CRS-HIPEC and CLM intervention offers long-term survival, suggesting that this treatment may be offered to selected patients with PM-CRC and CLM.

show abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: outcomes from a national centre in the current era

Cited by 2 publications

References 23 publications

Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends

Adoption of cytoreductive surgery in the management of peritoneal malignancies—Global trends

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer

Contact Info

Product

Resources

About